Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?
- Fate Therapeutics (FATE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 01/30/2024
|
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
- When billionaire investors step into a particular smaller-cap under-the-radar name, investors take notice. That appears to be the case with Fate Therapeutics (NASDAQ: FATE ) today.
- 01/29/2024
|
Fate Therapeutics (FATE) Upgraded to Buy: Here's Why
- Fate Therapeutics (FATE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/22/2023
|
Fate Therapeutics: Getting There, But Perpetually
- Fate Therapeutics stock has fallen 50% and lost 90% of its market cap, validating negative stance on the company. Janssen walked away from a partnership deal with Fate, resulting in a huge loss for shareholders. Fate's current pipeline consists of early-stage programs, but the company's progress in the market has been dubious.
- 11/12/2023
|
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
- FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
- 11/09/2023
|
Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript
- Fate Therapeutics, Inc. (NASDAQ:FATE ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer Conference Call Participants Ashiq Mubarack - Citigroup Inc. Tyler Van Buren - TD Cowen Daina Graybosch - Leerink Partners Kelsey Goodwin - Guggenheim Securities Peter Lawson - Barclays Yanan Zhu - Wells Fargo Etzer Darout - BMO Capital Markets Mara Goldstein - Mizuho Securities Operator Welcome to the Fate Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are mode.
- 11/08/2023
|
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
- SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023 financial results and provide a corporate update.
- 10/25/2023
|
Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?
- Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
- 09/07/2023
|
Fate Therapeutics to Present at Upcoming September Investor Conferences
- SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
- 08/31/2023
|
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
- FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.
- 08/09/2023
|
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
- Fate Therapeutics (FATE) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.79 per share a year ago.
- 08/08/2023
|
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
- SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023 at 5:00 PM ET to report its second quarter 2023 financial results and provide a corporate update.
- 07/28/2023
|
Why Shares of Fate Therapeutics Soared This Week
- Fate Therapeutics is a clinical-stage biotech. The company focuses on cell-derived oncology and immunology therapies.
- 06/16/2023
|
Fate Therapeutics: The Future Remains Cloudy
- Shares of off-the-shelf cell therapy concern Fate Therapeutics, Inc. have cratered 95% since reaching an all-time high in January 2021, punctuated by the termination of its Johnson & Johnson deal. The company has essentially hit the reset button, discontinuing four programs while laying off 60% of its staff.
- 05/23/2023
|
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.68 per share a year ago.
- 05/03/2023
|
Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know
- Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/03/2023
|
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
- SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 3, 2023 at 5:00 PM ET to report its first quarter 2023 financial results and provide a corporate update.
- 04/24/2023
|
Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report?
- Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
- 03/30/2023
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 03/27/2023
|
Fate Therapeutics to Present at Upcoming March Investor Conferences
- SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
- 03/03/2023
|
Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call Transcript
- Fate Therapeutics, Inc. (NASDAQ:FATE ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Chief Medical Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Carly Kenselaar - Citi Daina Graybosch - SVB Securities Tazeen Ahmad - Bank of America Andrea Tan - Goldman Sachs Robyn Karnauskas - Truist Mara Goldstein - Mizuho Matthew Biegler - Oppenheimer Operator Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 02/28/2023
|
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of 32.56% and 124.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2023
|
The 5 Best and Worst Performing Small-Cap Stocks in January 2023
- Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market.
- 02/13/2023
|
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
- SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, February 28, 2023 at 5:00 PM ET to report its fourth quarter and full year 2022 financial results and provide a corporate update.
- 02/13/2023
|
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
- 01/26/2023
|
Down -52.57% in 4 Weeks, Here's Why Fate Therapeutics (FATE) Looks Ripe for a Turnaround
- Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 01/19/2023
|
5 Best and Worst Performing Small-Cap Stocks in Dec 2022
- Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.
- 01/17/2023
|
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 01/10/2023
|
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
- Layoffs have been making headlines so far in 2023, even though we're just a few days into the new year. That's true even for gene-editing stocks.
- 01/06/2023
|
FATE To End Janssen Deal and Prioritize Pipeline Development
- FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
- 01/06/2023
|
Why Is Fate Therapeutics (FATE) Stock Down 62% Today?
- Fate Therapeutics (NASDAQ: FATE ) stock is falling hard on Friday after the company announced the termination of its collaboration with Janssen Biotech. Janssen was seeking to continue its collaboration with Fate Therapeutics with revised terms and conditions.
- 01/06/2023
|
Tesla Falls Again, but This Nasdaq Stock Is Truly Plunging
- The Nasdaq Composite once again is underperforming the rest of the market.
- 01/06/2023
|
Fate Therapeutics stocks heads for record selloff after Janssen collaboration terminated and job cuts
- Shares of Fate Therapeutics Inc. FATE, -1.08% plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of its collaboration with Janssen Biotech Inc. and announced job cuts. The company said it had declined Janssen's proposal to continue the collaboration on “revised terms and conditions.
- 01/06/2023
|
3 Graham's Lost Formula Picks to Consider for the New Year
- After ending 2022 on a low note, U.S. market indexes continued to sink on Thursday morning after jobs data showed the labor market is still hot despite the Federal Reserve's attempts to curb inflation. According to CNBC, the ADP private payrolls report indicated employers added 235,000 jobs in December, which was higher than economists' estimates.
- 01/05/2023
|
Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength?
- Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 01/05/2023
|
Fate Therapeutics: iPSC Pioneer A Buy For Long-Term Investors
- Shares have fallen by over 80% during the past 12 months. iPSC-derived NK cell programs sport advantages such as streamlined manufacturing, optimization and convenient administration.
- 01/05/2023
|
Fate Therapeutics (FATE) Loses -50.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 01/03/2023
|
Fate Therapeutics: Returning To The Ticker That Changed The Way I Invest
- Fate Therapeutics was one of my favorite investments, however, I made the haunting mistake of closing the position only to see the ticker nearly triple. This time will be different. FATE has lost roughly 60% over the past twelve months. I believe the ticker is trading near a reasonable valuation for its upside potential. I reveal my strategy.
- 11/15/2022
|
Fate Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
- 11/04/2022
|
Fate Therapeutics, Inc. (FATE) Q3 2022 Earnings Call Transcript
- Fate Therapeutics, Inc. (NASDAQ:FATE ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer Conference Call Participants Tazeen Ahmad - Bank of America Michael Yee - Jefferies Tyler Van Buren - Cowen Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Securities Daina Graybosch - SVB Securities Peter Lawson - Barclays Gil Blum - Needham Operator Welcome to the Fate Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode.
- 11/03/2022
|
Fate Therapeutics to Participate at Upcoming September Investor Conferences
- SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- 09/02/2022
|
The 5 Top Stocks Cathie Wood Is Buying Now
- Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The performance was driven by the release of July's consumer price index (CPI) report.
- 08/15/2022
|
3 Cathie Wood Stocks for the Future
- Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.
- 08/14/2022
|
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
- Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood's exchange-traded funds (ETFs). Fate is a clinical stage biotechnology company that develops cellular immunotherapies for patients with cancer and immune disorders.
- 08/12/2022
|
ARK's Cathie Wood Dumps More Twitter Stock, Buys $20M in Fate Therapeutics Stock
- Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm's exchange-traded funds (ETF) valued at over $20 million based on Thursday's closing pri
- 08/12/2022
|
7 Small-Cap Stocks to Buy Before the Bull Market Returns
- Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-term growth potential.
- 08/07/2022
|
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
- FATE reports a narrower loss and higher collaboration revenues in the second quarter.
- 08/04/2022
|
Fate Therapeutics Inc. (FATE) CEO Scott Wolchko on Q2 2022 Results - Earnings Call Transcript
- Fate Therapeutics Inc. (NASDAQ:FATE ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Kelsey Goodwin - Guggenheim Securities Tyler Van Buren - Cowen Ashiq Mubarack - Citigroup Michael Yee - Jefferies James Shin - Abbott Matt Biegler - Oppenheimer Daina Graybosch - SVB Securities Robyn Kay Karnauskas - Truist Securities Operator Welcome to the Fate Therapeutics Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, today's call is being recorded.
- 08/04/2022
|
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2022
|
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
- SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 3, 2022 at 5:00 PM ET to report its second quarter 2022 financial results and provide a corporate update.
- 07/25/2022
|
Trial Results Set to Make or Break Small-Cap Pharma Stocks
- One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.
- 07/06/2022
|
7 Small-Cap Stocks to Buy in July 2022
- These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.
- 07/04/2022
|
Nkarta Stock a Bargain Compared to Fate Therapeutics
- Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).
- 06/08/2022
|
Fate: Possible Speedy FDA Approval Process With RMAT Designation
- Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory diffuse large B-cell lymphoma. If all goes well with FDA meeting for FT516, then a pivotal study should begin in the second half of 2022.
- 06/03/2022
|
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
- Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
- 06/03/2022
|
Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
- SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 AM ET in New York, New York.
- 06/03/2022
|
Fate Therapeutics to Present at Upcoming May Investor Conferences
- SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
- 05/06/2022
|
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
- FATE reports a narrower loss and higher collaboration revenues in the first quarter.
- 05/05/2022
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2022 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko - Founder, President & Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Daina Graybosch - SVB Securities Nick Abbott - Wells Fargo Kelsey Goodwin - Guggenheim Mara Goldstein - Mizuho Robyn Karnauskas - Truist Securities Operator Welcome to the Fate Therapeutics First Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode.
- 05/04/2022
|
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2022
|
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
- Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/27/2022
|
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results
- SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 4, 2022 at 5:00 PM ET to report its first quarter 2022 financial results and provide a corporate update.
- 04/22/2022
|
Fate Therapeutics (FATE) Up 21.9% Since Last Earnings Report: Can It Continue?
- Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
- 03/30/2022
|
Biotech is ‘oversold': top stocks to capitalize on the pullback
- The SPDR S&P Biotech ETF is down close to 25% year-to-date but Michael Yee sees several names in this space that look promising at current valuations. Why did XBI recover in recent weeks?
- 03/28/2022
|
Fate Therapeutics to Present at Upcoming March Investor Conferences
- SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
- 03/02/2022
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2021 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.88% and 30.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
- SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Monday, February 28, 2022 at 5:00 PM ET to report its fourth quarter and full year 2021 financial results and provide a corporate update.
- 02/16/2022
|
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
- Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc FATE and Century Therapeutics Inc IPSC, an analyst at BofA Securities said in a note on Tuesday. The Biopharma Analyst: Tazeen Ahmad has a Buy rating and $112 price target on Fate shares.
- 02/08/2022
|
12 Super Small-Cap Stocks to Buy for 2022 and Beyond
- A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.
- 01/05/2022
|
Fate Therapeutics Stock (FATE): Why The Price Increased Today
- The stock price of Fate Therapeutics, Inc. (NASDAQ: FATE) increased by 2.43% today. This is why it happened.
- 12/14/2021
|
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
- Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the American Society of Hematology (ASH) Annual Meeting and Exposition. In the second, third, and fourth dose cohorts of monotherapy and combination arms comprising 26 patients, 18 patients (69%) achieved an objective response, including 12 patients (46%) that achieved a complete response, on Day 29 following a single dose of FT596.
- 12/14/2021
|
3 Biotech Stocks That Can Double Your Money, According to Wall Street
- All three of these stocks could rise over 100% once stock-market sentiment falls in line with the opinions of investment-bank analysts.
- 11/25/2021
|
Fate Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:
- 11/11/2021
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2021 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2021 Results - Earnings Call Transcript
- 11/05/2021
|
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of 1.72% and 64.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
3 Biotech Stocks to Watch Now
- Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.
- 10/12/2021
|
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
- SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Company's induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021.
- 10/01/2021
|
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
- Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.
- 09/14/2021
|
Cathie Wood Makes Adjustments to Portfolio in August
- Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.
- 09/13/2021
|
Fate Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:
- 09/02/2021
|
Why Fate Therapeutics Stock Is Sliding Today
- The positive results the company announced after the bell yesterday didn't meet some lofty expectations.
- 08/20/2021
|
Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
- Fate Therapeutics Inc (NASDAQ: FATE) revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma. At the 2021 American Society of Clinical Oncology Meeting, the Company highlighted positive interim FT516 program data for 11 pretreated patients.
- 08/20/2021
|
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
- 10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy
- 08/19/2021
|
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
- FATE reports a wider loss on increased R&D expenses in the second quarter.
- 08/05/2021
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2021 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2021 Results - Earnings Call Transcript
- 08/04/2021
|
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
- Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus
- 08/02/2021
|
Did You See What Cathie Wood Bought on Wednesday?
- ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.
- 07/22/2021
|
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
- SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET.
- 07/16/2021
|
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
- SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 5:00 p.m. ET to report its second quarter 2021 financial results and provide a corporate update.
- 07/15/2021
|
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
- IDNA: Genetics Now Have A Lot Of Influence On Healthcare
- 07/10/2021
|
Cathie Wood's ARK Invest Buys Over 530,000 Shares of Fate Therapeutics
- One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday.
- 07/08/2021
|
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
- SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Officer. Dr. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical operations, having led teams in the commercial-scale cGMP manufacture and distribution, as well as the clinical-stage process, assay, and formulation development, of complex biologics. As Chief Technical Officer, Mark will oversee the Company's manufacturing, technical, and supply chain operations.
- 06/15/2021
|
Fate Therapeutics: Strong Early Stage Data
- Fate Therapeutics is a pioneer in induced pluripotent stem cell research. They have been a research company mainly for nearly 15 years.
- 06/13/2021
|
The Rally Likely To Continue For Fate Therapeutics After Positive Clinical Trials Data
- The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading days, and we believe the stock will likely continue to rally in the near term.
- 06/10/2021
|
Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21
- Fate Therapeutics Inc (NASDAQ: FATE) has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell lymphoma. Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 06/04/2021
|
Why Is Fate Therapeutics (FATE) Down 12.2% Since Last Earnings Report?
- Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
- 06/04/2021
|
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting
- 8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response
- 06/04/2021
|
The Best Biotech Stocks to Buy With $500
- A modest amount goes a long way when you invest in biotech stocks.
- 05/31/2021
|
Fate Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:
- 05/25/2021
|
Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients
- Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML). Data come from two Phase 1 dose-escalation studies that are evaluating FT516 and FT538 as monotherapy.
- 05/14/2021
|
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
- FATE reports a wider Q1 loss on increased R&D expenses.
- 05/06/2021
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2021 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2021
|
ARK Genomic Revolution ETF: Value Realization Will Take Time
- ARK Genomic Revolution ETF: Value Realization Will Take Time
- 05/03/2021
|
Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
- Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline
- 04/27/2021
|
3 Hot Healthcare Stocks Cathie Wood Is Buying in April
- Here's why she likes them so much.
- 04/17/2021
|
Immunocore: 'Off-The-Shelf' T Cell Therapy
- Immunocore: 'Off-The-Shelf' T Cell Therapy
- 04/12/2021
|
3 of the Most Innovative Stocks to Buy Now
- Here's how shares a diversified e-commerce firm, an immunotherapy biotech, and an electronic agreement company can make you rich.
- 04/02/2021
|
Eli Casdin on looking for opportunity in life sciences
- Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.
- 04/01/2021
|
Regenerative Medicine Attracted Record $20 Billion in Funding in 2020
- Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
- 03/23/2021
|
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
- If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines appeared first on InvestorPlace.
- 03/12/2021
|
Fate Therapeutics to Present at Upcoming Investor Conferences
- SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the following upcoming investor conferences:
- 03/08/2021
|
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses
- FATE reports a wider Q4 loss on increased R&D expenses.
- 02/25/2021
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2020 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Fate Therapeutics: Q4 Earnings Insights
- Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61), which missed the estimate of ($0.39).
- 02/24/2021
|
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
- Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3
- 02/24/2021
|
Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 5:00 p.m. EST.
- 02/22/2021
|
2 Best Biotech Stocks to Buy in January
- These two companies are at the forefront of innovation during our golden age of biotech.
- 01/28/2021
|
Time To Book Profit In Fate Therapeutics Stock After A 5x Rally?
- After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has reached its near-term potential.
- 01/22/2021
|
Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity
- Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.
- 01/16/2021
|
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of 5,122,807 shares of its common stock, which included 701,754 shares that were issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $85.50 per share. In addition, in lieu of common stock to certain investors, the Company announced the closing of an underwritten public offering of pre-funded warrants to purchase 257,310 shares of its common stock at a purchase price of $85.499 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. Aggregate net proceeds from this offering are expected to be approximately $432 million after deducting underwriting discounts and commissions and other estimated offering expenses. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes.
- 01/08/2021
|
Is the Options Market Predicting a Spike in Fate Therapeutics (FATE) Stock?
- Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.
- 01/08/2021
|
Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 4,421,053 shares of its common stock at a public offering price of $85.50 per share. In addition, in lieu of common stock to certain investors, the Company announced the pricing of an underwritten public offering of pre-funded warrants to purchase 257,310 shares of its common stock at a purchase price of $85.499 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. This represents an aggregate offering of approximately $400 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 701,754 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $376 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters' option. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by Fate Therapeutics. The offering is expected to close on or about January 8, 2021, subject to customary closing conditions.
- 01/06/2021
|
3 Biotech Stocks That Could Double Your Money in 2021
- Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.
- 01/05/2021
|
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
- SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of $350 million of shares of common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes. In connection with the offering, Fate Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock offered in the public offering. All shares of common stock to be sold in the offering will be offered by Fate Therapeutics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- 01/04/2021
|
Here's a Cancer-Killing Stock to Buy for 2021
- "Natural killer" (or NK) cancer therapies are hot right now. Here are two stocks that are early leaders in the field -- one is a buy, and the other one is not.
- 12/30/2020
|
5 Biotech Stocks That Have Gained More Than 200% in 2020
- Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
- 12/29/2020
|
FATE Surges More Than 152% in Three Months: Here's Why?
- FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.
- 12/28/2020
|
Here's Why Fate Therapeutics' Data Produced a 38% Jump in the Stock Price
- The biotech's natural killer cell therapies have real potential.
- 12/23/2020
|
5 Biotech Stocks That More Than Doubled This Year
- The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
- 12/21/2020
|
Fate Therapeutics Stock Price Increases 37.8%: Why It Happened
- The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 37.8% (from $60.79 on December 6 to $83.77 on December 7). This is why.
- 12/08/2020
|
Why Fate Therapeutics Stock Is Skyrocketing Today
- The biotech reported great news on Friday and Saturday for two of its cancer immunotherapy candidates.
- 12/07/2020
|
Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma
- Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells
- 12/06/2020
|
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
- 3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response
- 12/04/2020
|
Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting
- SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event entitled “The Power of hnCD16” on Friday, December 4, 2020 at 4:30 PM EDT.
- 11/30/2020
|
Fate Therapeutics Announces Participation in Upcoming Investor Conferences
- SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:
- 11/12/2020
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript
- 11/06/2020
|
Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
- First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma
- 11/05/2020
|
CAR-T Pipeline Insights Report 2020: Comprehensive Insights on 250+ Companies and Pipeline Drugs - ResearchAndMarkets.com
|
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
- SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointed Chief Financial Officer. Mr. Dulac comes to the Company from Celgene Corporation, where he most recently served as Vice President, Business Development & Strategy, and brings an extensive array of biopharmaceutical experience having served for over 20 years in positions in finance, business development, and product portfolio strategy. “Ed is an outstanding addition to our leadership team, bringing to Fate Therapeutics great strategic and operational insight into the building and managing of an industry-leading hematology franchise,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “His integrated perspective across the strategic, clinical, and commercial elements of cell-based cancer immunotherapy is of great value as we clinically advance our off-the-shelf, iPSC-derived cell product candidates in hematologic malignancies and leverage our proprietary iPSC product platform through strategic partnerships.”“Fate Therapeutics is at the forefront of off-the-shelf, cell-based cancer immunotherapy, and I can’t imagine a more exciting time to join as the Company advances its first-of-kind product candidates through early clinical development,” said Mr. Dulac. “The Company’s proprietary iPSC product platform is capable of creating multiplexed engineered cell therapies with the potential to successfully treat serious cancers and other debilitating diseases, and I am eager to help bring these new therapies to patients.”In his most recent role of Vice President of Business Development & Strategy at Celgene, Mr. Dulac was responsible for business development opportunities in the therapeutic areas of hematology and oncology, inflammation and immunology, and neuroscience. During his tenure at Celgene, he also held various positions of increasing responsibility in the company’s hematology and oncology franchise, including portfolio development strategy and commercial planning. Prior to Celgene, Mr. Dulac worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers and in corporate finance at Pfizer. Mr. Dulac received a B.S. in Pharmacy from the University of Pittsburgh and an M.B.A. from the Kelley School of Business at Indiana University.In connection with his commencement of employment, Fate Therapeutics granted Mr. Dulac an option to purchase 160,000 shares of the Company’s common stock with an exercise price equal to $35.52, the closing price per share of the Company’s common stock as reported by NASDAQ on August 17, 2020, which was the date of commencement of Mr. Dulac’s employment with the Company and the effective date of grant. The option is a non-qualified stock option and vests over a period of four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in approximately equal monthly increments over the succeeding thirty-six months, subject to Mr. Dulac’s continuous employment through each vesting date. In addition, Fate Therapeutics granted Mr. Dulac an award of 40,000 restricted stock units, with each restricted stock unit equal to one share of the Company’s common stock. Twenty-five percent (25%) of the restricted stock units vest on the one-year anniversary of the date of commencement of employment, and thereafter twenty-five percent (25%) of the restricted stock units shall vest on each anniversary of the date of commencement of employment, subject to Mr. Dulac’s continuous employment through each vesting date. The option and the restricted stock unit award each were granted as an inducement material to Mr. Dulac entering into employment with Fate Therapeutics in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the Company’s Inducement Equity Plan.About Fate Therapeutics’ iPSC Product Platform The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of, plans related to, and the therapeutic potential of the Company's product candidates, the Company’s clinical development strategy, and the Company’s plans for the clinical investigation of its product candidates. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of difficulties or delay in the initiation of any planned clinical studies, or in the enrollment or evaluation of subjects in any future clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of the Company’s product candidates may not be replicated in ongoing or future clinical trials or studies, and the risk that the Company’s product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com
- 08/19/2020
|
What Kind Of Shareholders Own Fate Therapeutics, Inc. (NASDAQ:FATE)?
- Every investor in Fate Therapeutics, Inc. (NASDAQ:FATE) should be aware of the most powerful shareholder groups. Large...
- 08/11/2020
|
How Much Of Fate Therapeutics, Inc. (NASDAQ:FATE) Do Institutions Own?
- The big shareholder groups in Fate Therapeutics, Inc. (NASDAQ:FATE) have power over the company. Large companies...
- 08/11/2020
|
Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2020
|
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
- Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for AML and Multiple MyelomaIND Cleared for FT819, the First iPSC-derived CAR T-cell Therapy, for Advanced B-cell Leukemias and LymphomasWorldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates Targeting up to Four Tumor-associated AntigensEnded Quarter with $533 Million in Cash & Short-term InvestmentsSAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the second quarter ended June 30, 2020.“Early clinical data from our FT596 program are very encouraging, as we observed a partial response in a heavily-pretreated patient with refractory diffuse large B-cell lymphoma at the first dose level without any reported events of cytokine release syndrome, neurotoxicity or graft-versus-host disease. Additionally, the safety, tolerability, and immunogenicity data across our off-the-shelf NK cell programs continue to suggest that multiple doses of iPSC-derived NK cells can be administered to a patient without matching,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “We continue to be pleased with our pace of innovation, where the recent clearances of our IND applications by the FDA for FT538, the first-ever CRISPR-edited iPSC-derived cell therapy, and for FT819, the first-ever iPSC-derived CAR T-cell therapy, continue to demonstrate our unique ability to rapidly bring multiplexed engineered, off-the-shelf NK cell and T-cell cancer immunotherapies to patients. In addition, we successfully launched our Janssen collaboration with strong momentum, bringing together Janssen’s proprietary tumor-targeting antigen binders and our industry-leading iPSC product platform to develop novel off-the-shelf CAR NK and CAR T-cell immunotherapies for hematologic malignancies and solid tumors.”Clinical Programs * Partial Response Reported with FT596 Monotherapy at First Dose Level. In June, the Company reported Day 29 protocol-defined response assessments for the first two patients treated with FT596, the Company’s off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-cancer modalities: a proprietary CD19-targeting chimeric antigen receptor (CAR), a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, and an IL-15/IL-15 receptor fusion. Each patient had previously been treated with at least four lines of therapy for diffuse large B-cell lymphoma (DLBCL), and was administered a single dose of FT596 as a monotherapy at the first dose level (30 million cells). The first patient had progressive disease, having most recently relapsed following treatment with an FDA-approved CD19-targeting CAR T-cell therapy. The second patient had a partial response, having most recently been refractory to an experimental donor-derived NK cell regimen. The FT596 response assessment in this patient showed a greater than 70% reduction in metabolic activity and a greater than 50% reduction in tumor size as assessed by PET-CT scan. No dose-limiting toxicities, no FT596-related serious adverse events (SAEs), and no events of cytokine release syndrome, neurotoxicity, or graft-versus-host disease were reported by investigators in either patient. * Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma. In addition to assessing FT596 as a monotherapy, the FT596 Phase 1 clinical trial includes the administration of FT596 in combination with rituximab, which enables dual-antigen targeting of CD19 and CD20 through the product candidate’s CAR and hnCD16 receptors, respectively. Enrollment into this dose-escalating regimen has been initiated at 30 million cells for patients with relapsed / refractory B-cell lymphoma. * Second FT516 IND Application Cleared by FDA for Advanced Solid Tumors. In April, the U.S. Food & Drug Administration (FDA) cleared an investigational new drug (IND) application for FT516, the Company’s off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express hnCD16 Fc receptor. The Phase 1 study, which is sponsored by investigators from the Masonic Cancer Center, University of Minnesota, is intended to assess intraperitoneal administration of three once-weekly doses of FT516, each with IL-2 cytokine support, for women with recurrent ovarian cancer. The Company is preparing to initiate a multi-dose Phase 1 clinical trial of FT516 in combination with avelumab, a checkpoint inhibitor therapy targeting PD-L1, for patients with advanced solid tumors, and is continuing to enroll a multi-dose Phase 1 clinical trial of FT516 as a monotherapy for patients with acute myeloid leukemia (AML) and in combination with CD20-directed monoclonal antibodies for patients with advanced B-cell lymphoma. * Evidence of Clinical Activity Observed with FT500 for Advanced Solid Tumors. In May 2020, the Company announced the completion of the dose-escalation stage of the FT500 Phase 1 clinical trial for advanced solid tumors, having enrolled three patients at the second dose level of FT500 in combination with checkpoint inhibitor therapy. Each of these three patients was previously treated with at least four lines of therapy, and most recently was refractory to, or had relapsed on, checkpoint inhibitor therapy. Evidence of clinical activity was observed in two patients, with one patient having a 58% reduction in the size of target lesions prior to discontinuing treatment during the second 30-day cycle due to non-target lesion formation and one patient having stable disease following completion of the second 30-day cycle. No dose-limiting toxicities, no FT500-related SAEs or Grade ≥3 adverse events, and no events of cytokine release syndrome, neurotoxicity, or graft-versus-host disease were reported by investigators in the dose-escalation stage of the study. The Company is enrolling the dose-expansion stage of the FT500 Phase 1 clinical trial and intends to treat up to 15 patients who are refractory to, or have relapsed on, checkpoint inhibitor therapy, administering three once-weekly doses of FT500 at 300 million cells per dose, each with IL-2 cytokine support, for up to two 30-day cycles in combination with the same checkpoint inhibitor on which the patient failed or relapsed. * IND Application Cleared by FDA for FT538, the First-ever CRISPR-edited, iPSC-derived Cell Therapy. In May 2020, the FDA cleared the Company’s IND application for FT538, its off-the-shelf NK cell product candidate derived from a clonal master iPSC line engineered with three functional components to enhance innate immunity: a novel hnCD16 Fc receptor; an IL-15/IL-15 receptor fusion; and the elimination of CD38 expression. The Company is preparing to initiate a multi-center Phase 1 clinical trial of three once-weekly doses of FT538 as a monotherapy for patients with relapsed / refractory AML and in combination with daratumumab for patients with relapsed / refractory multiple myeloma. * IND Application Cleared by FDA for FT819, the First-ever iPSC-derived CAR T-cell Therapy. In June 2020, the FDA cleared the Company’s IND application for FT819, an off-the-shelf allogeneic CAR T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy including: a novel 1XX CAR signaling domain, which has been shown to extend T-cell effector function without eliciting exhaustion; integration of the CAR transgene directly into the T-cell receptor alpha constant (TRAC) locus, which has been shown to promote uniform CAR expression and enhanced T-cell potency; and complete bi-allelic disruption of T-cell receptor expression for the prevention of graft-versus-host disease, a potentially life-threatening complication associated with allogeneic T-cell therapy. The Company is preparing to initiate a multi-center Phase 1 clinical trial of FT819 for patients with chronic lymphocytic leukemia, acute lymphoblastic leukemia, or B-cell lymphoma. Each indication will enroll independently and evaluate three dose-escalating treatment regimens: a single dose of FT819; a single dose of FT819 with IL-2 cytokine support; and three fractionated doses of FT819. * Investigator-initiated Clinical Trial of FT516 for COVID-19 Opened to Enrollment. Investigators from the Department of Medicine, Division of Infectious Diseases and International Medicine, University of Minnesota are currently enrolling a Phase 1 clinical trial of FT516 in up to 20 patients with Coronavirus Disease 2019 (COVID-19) at high risk of developing critical life-threatening illness.Preclinical Programs * Four Anti-Tumor Modalities of FT576 for Multiple Myeloma Highlighted at ASGCT. The Company presented new preclinical data for FT576, its off-the-shelf, iPSC-derived, multi-antigen targeted CAR-BCMA NK cell product candidate for multiple myeloma, at the American Society of Gene & Cell Therapy (ASGCT) Virtual Annual Meeting in May. In a serial re-stimulation cytotoxicity assay against an MM1.R myeloma cell line, FT576 was shown to be resistant to anti-CD38 monoclonal antibody induced fratricide and to have enhanced cytotoxicity both as a monotherapy and in combination with daratumumab as compared to daratumumab alone.
- 08/05/2020
|
Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
- Stocks Analysis by Zacks Investment Research covering: S&P 500, Fate Therapeutics Inc. Read Zacks Investment Research's latest article on Investing.com
- 08/05/2020
|
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
- SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Scientific Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020, at 11:30 a.m. EST. A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com
- 08/04/2020
|
Sumitomo Mitsui Trust Holdings Inc. Has $18.26 Million Position in Fate Therapeutics Inc (NASDAQ:FATE)
- Sumitomo Mitsui Trust Holdings Inc. lessened its stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 42.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 532,204 shares of the biopharmaceutical company’s stock after selling 393,805 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s […]
- 08/04/2020
|
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
- SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 5:30 p.m. ET to report its second quarter 2020 financial results and provide a corporate update. In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 8295527. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com
- 07/29/2020
|
Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players
- 47.6% single-year revenue increase on the guidance of an additional 15% sales growth in 2021. 67% capital gains YoY with a 4% downside risk in the same period.
- 07/28/2020
|
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/28/2020
|
Could Fate Therapeutics Be a Millionaire-Maker Stock?
- Thanks to its powerful platform that enables the efficient mass production of high-impact and high-complexity cellular therapies for cancers and immune disorders, its manufacturing technology licensing revenues alone could be a gold mine. Historically, gathering non-induced stem cells required a donation of human cord blood, making them both expensive to produce and variable from donor to donor, in terms of their cellular properties. Manufacturing iPSCs in small numbers without a human donor isn't new, but the company's innovation is to genetically engineer and culture its iPSCs at scale by generating homogenous cell lines that can be cloned or expanded indefinitely without additional donations.
- 07/26/2020
|
Vident Investment Advisory LLC Sells 32,314 Shares of Fate Therapeutics Inc (NASDAQ:FATE)
- Vident Investment Advisory LLC lessened its position in Fate Therapeutics Inc (NASDAQ:FATE) by 42.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,580 shares of the biopharmaceutical company’s stock after selling 32,314 shares during the quarter. Vident Investment Advisory […]
- 07/22/2020
|
2 Stocks to Hold for the Next 20 Years
- Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.
- 07/21/2020
|
Were Hedge Funds Right About Piling Into Fate Therapeutics Inc (FATE)?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 07/16/2020
|
Analysts Anticipate Fate Therapeutics Inc (NASDAQ:FATE) Will Announce Quarterly Sales of $20.33 Million
- Brokerages expect that Fate Therapeutics Inc (NASDAQ:FATE) will post $20.33 million in sales for the current quarter, according to Zacks. Nine analysts have provided estimates for Fate Therapeutics’ earnings, with the lowest sales estimate coming in at $2.50 million and the highest estimate coming in at $54.63 million. Fate Therapeutics posted sales of $2.82 million […]
- 07/16/2020
|
Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies
- License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Durable Tumor EradicationSAN DIEGO, July 14, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company entered into an exclusive license agreement with Baylor College of Medicine covering alloimmune defense receptors, a first-in-class approach that renders off-the-shelf allogeneic cell products resistant to host immune rejection. Preclinical studies published in the journal Nature Biotechnology (https://www.nature.com/articles/s41587-020-0601-5) demonstrate that allogeneic cells engineered with a novel alloimmune defense receptor (ADR) are protected from both T- and NK-cell mediated rejection, and provide proof-of-concept that ADR-expressing allogeneic cell therapies can durably persist in immunocompetent recipients.“Allogeneic cell therapy requires a patient to endure systemic lympho-conditioning to suppress the immune system and mitigate cellular rejection, often resulting in severe blood cell deficiencies and related toxicities. There is great interest in strategies that enable allogeneic cells to overcome host immunity and evade immune rejection while maintaining a patient’s functional hematopoietic system,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “The published preclinical data provide compelling evidence that allogeneic cell therapies armed with novel alloimmune defense receptors can effectively abrogate both T- and NK-cell rejection responses and can persist and remain functional in immunocompetent patients.”ADRs are synthetic receptors that selectively recognize cell surface receptors, such as 4-1BB, that are uniquely expressed on activated lymphocytes, which are responsible for host immune rejection. The published preclinical findings show that the arming of allogeneic T cells with an ADR selectively eliminates alloreactive T and NK cells, while sparing resting lymphocytes. Importantly, in in vivo preclinical models of cancer, allogeneic T cells expressing both an ADR and a CD19-targeted chimeric antigen receptor (CAR) demonstrated increased expansion and persistence, resulting in sustained tumor eradication and a long-term survival benefit compared to conventional CD19-targeted CAR T cells.“There is tremendous promise for the use of off-the-shelf allogeneic cells as replacement therapy. One of the most significant barriers to overcome is host immunity, which can prevent the engraftment of allogeneic cells and the long-term replacement of a patient’s damaged or dysfunctional cells,” said Maksim Mamonkin, Ph.D., Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine and the senior author on the Nature Biotechnology publication. “We are excited for Fate Therapeutics to explore the use of alloimmune defense receptors in the development of rejection-resistant, iPSC-derived cellular therapies.”About Fate Therapeutics’ iPSC Product Platform The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company’s NK and T-cell product candidates and preclinical research and development programs, and the scope and enforceability of the Company’s intellectual property portfolio. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of its product candidates may not be replicated in ongoing or future clinical trials or studies, the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and the risk that any of the patents owed or licensed by the Company may be challenged and that such a challenge may be successful, resulting in loss of any such patent or loss or reduction in the scope of one or more of the claims of a challenged patent. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com
- 07/14/2020
|
Axa Purchases Shares of 25,900 Fate Therapeutics Inc (NASDAQ:FATE)
- Axa purchased a new position in Fate Therapeutics Inc (NASDAQ:FATE) in the first quarter, HoldingsChannel reports. The institutional investor purchased 25,900 shares of the biopharmaceutical company’s stock, valued at approximately $575,000. Several other large investors also recently bought and sold shares of the company. Meeder Asset Management Inc. raised its position in shares of Fate […]
- 07/12/2020
|
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
- Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.
- 07/10/2020
|
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
- FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819.
- 07/09/2020
|
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)
AbbVie Inc (NYSE: ABBV)...
- 07/08/2020
|
The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 6)
ACADIA Pharmaceuticals Inc...
- 07/07/2020
|
AQR Capital Management LLC Raises Stock Holdings in Fate Therapeutics Inc (NASDAQ:FATE)
- AQR Capital Management LLC increased its position in Fate Therapeutics Inc (NASDAQ:FATE) by 175.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,479 shares of the biopharmaceutical company’s stock after acquiring an additional 33,393 shares during the period. AQR Capital Management LLC […]
- 07/05/2020
|
Nuveen Asset Management LLC Grows Position in Fate Therapeutics Inc (NASDAQ:FATE)
- Nuveen Asset Management LLC grew its position in Fate Therapeutics Inc (NASDAQ:FATE) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 388,773 shares of the biopharmaceutical company’s stock after buying an additional 46,368 shares during the quarter. […]
- 06/24/2020
|
Notable Insider Buys Last Week: Cigna, Fox, Uber And More
- Insider buying can be an encouraging signal for potential investors.
Some insiders took advantage of a secondary offering last week.
Two chief executives also have stepped up to...
- 06/20/2020
|
AlphaCrest Capital Management LLC Purchases New Position in Fate Therapeutics Inc (NASDAQ:FATE)
- AlphaCrest Capital Management LLC purchased a new stake in Fate Therapeutics Inc (NASDAQ:FATE) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 9,460 shares of the biopharmaceutical company’s stock, valued at approximately $210,000. Other institutional investors have also made changes to their positions in […]
- 06/16/2020
|
Hedge Funds Keep Buying Fate Therapeutics Inc (FATE)
- In this article we will check out the progression of hedge fund sentiment towards Fate Therapeutics Inc (NASDAQ:FATE) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]
- 06/15/2020
|
If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now
- Here's how much you'd have if you'd invested in this mid-cap biotech company that's developing the next generation of cancer immunotherapies.
- 06/13/2020
|
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of 7,108,796 shares of its common stock, which included 927,324 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $28.31 per share. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes.
- 06/11/2020
|
Global CAR-T Therapy Market Assessment 2020-2030 - ResearchAndMarkets.com
|
Fate Therapeutics (NASDAQ:FATE) Coverage Initiated at Oppenheimer
- Analysts at Oppenheimer assumed coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research report issued on Tuesday, TipRanks reports. The firm set a “buy” rating and a $40.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 22.25% from the stock’s current price. Other equities research analysts […]
- 06/10/2020
|
Here's Why Fate Therapeutics Rose 18.4% in May
- On May 20, the development-stage company announced the U.S. Food and Drug Administration (FDA) cleared a new drug candidate to begin clinical trials. Identified as FT538, the drug candidate is the first cell therapy that has been both engineered with CRISPR gene-editing tools and derived from induced pluripotent stem cells (iPSC).
- 06/09/2020
|
Here's Why Fate Therapeutics Stock Jumped Higher Today
- Shares of Fate Therapeutics (NASDAQ: FATE) were up 19% to $33.73 at 1:39 p.m. EDT on Tuesday after the company raised at least $214 million through a public secondary offering and a private placement with Johnson & Johnson (NYSE: JNJ). After subtracting underwriting discounts and commissions and other expenses, Fate expects to net about $164.2 million. In addition to the public offering, Fate will also sell $50 million worth of shares to Johnson & Johnson at the same offering price of $28.31.
- 06/09/2020
|
Fate Therapeutics shares are trading. The company late Monday priced its 6.18 million share common stock offering at $28.31 per share.
|
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 6,181,562 shares of its common stock at a public offering price of $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 927,234 shares of its common stock.
- 06/09/2020
|
The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 8)
Biohaven Pharmaceutical...
- 06/09/2020
|
Fate Therapeutics Announces Proposed Public Offering of Common Stock; No Terms Disclosed
|
Fate Therapeutics Announces Proposed Public Offering of Common Stock
- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning and qualification of its new facility, the conduct of preclinical research and development, and for general corporate purposes.
- 06/08/2020
|
Fate Therapeutics Inc (NASDAQ:FATE) Shares Purchased by State Street Corp
- State Street Corp raised its stake in Fate Therapeutics Inc (NASDAQ:FATE) by 3.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,465,539 shares of the biopharmaceutical company’s stock after buying an additional 81,407 shares during the quarter. State Street Corp owned about 3.25% […]
- 06/07/2020
|
Zweites Gentherapieprodukt von Vivet, VTX-803 für PFIC3, in den USA und der EU als Arzneimittel für seltene Leiden (Orphan Drug) anerkannt
- Vivet Therapeutics meldete heute, dass sowohl die US-Food and Drug Administration (FDA) als auch die Europäische Kommission (EC) VTX-803, das zweite G
- 06/01/2020
|
Stocks Trading Above 52 Week Low and Below 52 Week High: $IOVA $CRBP $FATE
- May 25, 2020 (The Market Signal via Comtex) --
Sector Reports was created as a platform to help investors find the best free Stock Reports on stocks they...
- 05/25/2020
|
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
- 05/22/2020
|
Fate Therapeutics Reports FDA Clearance For Investigational New Drug Application For FT538, CRISPR-Edited, iPSC-Derived Cell Therapy
|
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. FT538 is an off-the-shelf natural killer (NK) cell cancer immunotherapy that is derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three functional components to enhance innate immunity: a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor; an IL-15/IL-15 receptor fusion (IL-15RF); and the elimination of CD38 expression.
- 05/20/2020
|
Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock
- This mid-cap biotech is developing a new type of cellular immunotherapy, and its potential has attracted the attention of many institutional investors.
- 05/15/2020
|
HC Wainwright & Co. Initiates Coverage On Fate Therapeutics with Buy Rating, Announces Price Target of $42
|
Fate Therapeutics Inc (FATE) Q1 2020 Earnings Call Transcript
- Good afternoon, and thanks everyone for joining us for the Fate Therapeutics first quarter 2020 financial results call. Additionally, it is one of the first ever clinical trials of a cell therapy to evaluate a novel multi-dose treatment course, consisting of outpatient lympho-conditioning followed by three once-weekly doses of FT500 over up to two 30-day treatment cycles.
- 05/12/2020
|
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
- This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.
- 05/12/2020
|
BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to $29
|
Edited Transcript of FATE earnings conference call or presentation 11-May-20 9:00pm GMT
- Q1 2020 Fate Therapeutics Inc Earnings Call
- 05/12/2020
|
U.S. RESEARCH ROUNDUP-Digital Realty Trust, Pilgrims Pride, Terraform Power
- Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Digital Realty Trust, Pilgrims Pride and Terraform Power,
on Tuesday.
HIGHLIGHTS
* Digital Realty Trust Inc : Citigroup cuts neutral from buy
* Pilgrims Pride Corp : Stephens raises to overweight from equal-weight
* Terraform Power Inc : RBC raises target price to $19 from $16
* Zimmer Biomet Holdings Inc : SunTrust Robinson raises TP to $132 from $125
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock
entries are in alphabetical order.
* Acceleron pharma Inc : Cowen and Company raises price target to $121 from $109
* Albemarle Corp : Citigroup raises price target to $59 from $49
* Alphabet Inc : Citigroup raises price target to $1600 from $1400
* Amag Pharmaceuticals Inc : Cowen and Company cuts price target to $5 from $9
* AMN Healthcare Services Inc : Credit Suisse cuts target price to $62 from $81
* Amneal Pharmaceuticals Inc : SVB Leerink raises target price to $4 from $3
* Arbor Realty Trust Inc : KBW raises target price to $8 from $6
* Arch Capital Group Ltd : KBW cuts target price to $36 from $39
* Autonation Inc : JP Morgan raises target price to $40 from $37
* Avaya Holdings Corp : Citigroup raises price target to $13 from $8
* Bancorp Inc : Piper Sandler cuts target price to $11 from $12
* Bloom Energy Corp : Cowen and Company raises price target to $8 from $6
* Bluebird Bio Inc : Piper Sandler cuts target price to $70 from $75
* Bluebird Bio Inc : SVB Leerink raises target price to $137 from $135
* Cable One Inc : Keybanc raises target price to $2,105 from $1,968
* Caesars Entertainment Corp : Jefferies raises target price to $10 from $7
* Cardinal Health Inc : Mizuho raises target price to $56 from $50
* Ceridian Hcm Holding Inc : Citigroup raises price target to $77 from $64
* Ceva Inc : Cowen and Company raises price target to $40 from $37
* Choice Hotels International Inc : Jefferies raises target price to $70 from $60
* Choice Hotels International Inc : JP Morgan cuts target price to $59 from $85
* Choice Hotels International Inc : SunTrust Robinson raises TP to $67 from $66
* Cleveland-Cliffs Inc : Citigroup raises price target to $5 from $3.5
* CNA Financial Corp : KBW cuts target price to $35 from $36
* Continental Resources Inc : Susquehanna raises target price to $12 from $10
* Cornerstone Ondemand Inc : D.A. Davidson cuts target price to $40 from $64
* Cornerstone Ondemand Inc : RBC raises target price to $37 from $33
* Crinetics Pharmaceuticals Inc : SVB Leerink cuts target price to $39 from $43
* Cushman & Wakefield Plc : Citigroup cuts price target to $12 from $21
* Cytokinetics Inc : Needham raises price target to $34 from $24
* Cytokinetics Inc : Piper Sandler raises target price to $28 from $22
* Datadog Inc : Credit Suisse raises target price to $55 from $45
* Datadog Inc : Jefferies raises target price to $59 from $39
* Datadog Inc : JP Morgan raises target price to $65 from $60
* DCP Midstream LP : Credit Suisse raises target price to $9 from $7
* Dicerna Pharmaceuticals Inc : Citigroup cuts price target to $32 from $35
* Digital Realty Trust Inc : Citigroup cuts neutral from buy
* Digital Realty Trust Inc : Citigroup raises price target to $150 from $140
* Eagle Pharmaceuticals Inc : Piper Sandler raises target price to $50 from $47
* eBay Inc : CFRA cuts to sell from hold; cuts target price by $2 to $35
* Eldorado Resorts Inc : Jefferies raises target price to $38 from $29
* Eloxx Pharmaceuticals Inc : Canaccord Genuity cuts target price to $6 from $17
* Evelo Biosciences Inc : Jefferies cuts target price to $6 from $18
* Evolus Inc : SunTrust Robinson cuts target price to $12 from $18
* Fate Therapeutics Inc : Jefferies raises target price to $37 from $36
* First Guaranty Bancshares Inc : Piper Sandler cuts target price to $14 from $22
* Genpact Ltd : Cowen and Company raises target price to $41 from $39
* Golub Capital BDC Inc : KBW cuts target price to $13.5 from $16
* Green Dot Corp : BTIG raises target price to $40 from $35
* Green Dot Corp : Jefferies raises target price to $32 from $27
* Grocery Outlet Holding Corp : Jefferies raises target price to $52 from $51
* IAC/InterActiveCorp : Citigroup raises price target to $285 from $240
* Ii-Vi Inc : D.A. Davidson raises target price to $45 from $40
* Ii-Vi Inc : Piper Sandler raises target price to $54 from $40
* Intercept Pharmaceuticals Inc : Raymond James cuts target price to $145 from $148
* Intersect Ent Inc : Piper Sandler cuts target price to $14 from $23
* Kvh Industries Inc : Raymond James cuts target price to $10 from $12
* Linde Plc : Citigroup raises price target to $216 from $209
* Livent Corp : Credit Suisse cuts target price to $5 from $6
* Macrogenics Inc : Credit Suisse raises target price to $30 from $13
* Magellan Health Inc : Jefferies raises target price to $85 from $81
* Marriott : JP Morgan cuts target price to $88 from $129
* Mustang Bio Inc : Oppenheimer cuts target price to $13 from $15
* Myokardia Inc : Citigroup raises price target to $125 from $87
* Myokardia Inc : Wedbush raises target price to $127 from $90
* ON Semiconductor Corp : Needham raises price target to $20 from $17
* Park Hotels & Resorts Inc : Jefferies cuts target price to $9 from $10
* Paycom Software Inc : Citigroup raises price target to $315 from $262
* Paylocity Holding Corp : Citigroup raises price target to $124 from $94
* Pennymac Mortgage Investment Trust : KBW raises target price to $11.5 from $10
* Pilgrims Pride Corp : Stephens raises to overweight from equal-weight
* Pilgrims Pride Corp : Stephens raises target price to $28 from $20
* PRA Group Inc : KBW raises target price to $42 from $35
* Purple Innovation Inc : Keybanc raises target price to $16 from $12
* Purple Innovation Inc : Raymond James raises target price to $16 from $10
* Rattler Midstream LP : Simmons Energy raises target price to $8 from $5
* Ready Capital Corp : Piper Sandler raises target price to $10 from $8
* Scientific Games Corp : JP Morgan cuts target price to $11 from $25
* Seaworld Entertainment Inc : Keybanc raises target price to $19 from $17
* Select Energy Services Inc : Citigroup raises price target to $5.5 from $3
* SS&C Technologies Holdings Inc : Citigroup raises price target to $67 from $50
* Synchronoss Technologies : Canaccord Genuity cuts target price to $10 from $13
* Targa Resources Corp : Simmons Energy raises target price to $13 from $8
* Tenet Healthcare Corp : Raymond James cuts target price to $40 from $48
* Terraform Power Inc : RBC raises target price to $19 from $16
* Terreno Realty Corp : Stifel cuts target price to $56 from $60
* Tilray Inc : Cowen and Company cuts target price to $9 from $15
* T-Mobile US Inc : Citigroup raises price target to $115 from $103
* Trade Desk Inc : Citigroup raises price target to $320 from $240
* Under Armour Inc : JP Morgan cuts target price to $8 from $9
* Under Armour Inc : Keybanc cuts target price to $16 from $23
* Under Armour Inc : Piper Sandler cuts target price to $10 from $11
* Under Armour Inc : Susquehanna cuts target price to $4 from $6
* Under Armour Inc : Telsey Advisory Group cuts target price to $8 from $9
* Under Armour Inc : Wedbush cuts target price to $10 from $11
* Western Midstream Partners LP : Citigroup cuts price target to $7 from $23
* Williams Companies Inc : Credit Suisse cuts to neutral from outperform
* Xenia Hotels & Resorts Inc : Jefferies cuts target price to $8.50 from $11
* Zillow Group Inc : Stephens raises target price to $68 from $48
* Zimmer Biomet Holdings Inc : Canaccord Genuity raises TP to $137 from $135
* Zimmer Biomet Holdings Inc : Citigroup raises price target to $140 from $125
* Zimmer Biomet Holdings Inc : Needham cuts target price to $148 from $153
* Zimmer Biomet Holdings Inc : Piper Sandler cuts target price to $160 from $175
* Zimmer Biomet Holdings Inc : SunTrust Robinson raises TP to $132 from $125
(Compiled by Bengaluru Newsroom)
- 05/12/2020
|
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2020 Results - Earnings Call Transcript
- Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Scott Wolchko - President & Chief Execut
- 05/12/2020
|
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
- Fate Therapeutics (FATE) delivered earnings and revenue surprises of -15.79% and 21.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Fate Therapeutics Q1 EPS $(0.440) Misses $(0.390) Estimate, Sales $2.515M Beat $1.800M Estimate
|
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the first quarter ended March 31, 2020. FT596 is the industry’s first investigational cellular immunotherapy engineered with three active anti-tumor modalities to be evaluated in patients.
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?
- Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/08/2020
|
Mantle Cell Lymphoma Treatment Market - Global Industry to Discern Magnified Growth During 2020-2027
- May 07, 2020 (Global QYResearch via COMTEX) --
This report studies the global Mantle Cell Lymphoma Treatment market status and forecast, categorizes the...
- 05/08/2020
|
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?
|
Were Hedge Funds Right About Fate Therapeutics Inc (FATE)?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 05/06/2020
|
Fate Therapeutics Announces Changes to its Board of Directors
- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the retirement of Amir Nashat, Sc.D., Managing General Partner at Polaris Venture Partners, from the Company’s board of directors. Dr. Nashat was the longest tenured member of the Company’s board, having served since the founding of Fate Therapeutics in 2007.
- 05/05/2020
|
Fate Therapeutics Announces Changes to its Board of Directors
|
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results
- SAN DIEGO, May 04, 2020 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.
- 05/04/2020
|
Why Earnings Season Could Be Great for Fate Therapeutics (FATE)
- Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/04/2020
|
Why Earnings Season Could Be Great for Fate Therapeutics (FATE)
|
Analysts' Weekly Ratings Changes for Fate Therapeutics (FATE)
- Several brokerages have updated their recommendations and price targets on shares of Fate Therapeutics (NASDAQ: FATE) in the last few weeks: 4/28/2020 – Fate Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $34.00 price target on the stock. According to Zacks, “Fate […]
- 05/01/2020
|
Did The Underlying Business Drive Fate Therapeutics’ (NASDAQ:FATE) Lovely 576% Share Price Gain?
- For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a...
- 04/30/2020
|
3 Monster Growth Stocks That Are Still Undervalued
- The market is on the move, and this time stocks took off on an upward trajectory. On Wednesday April 29, all three of the major U.S. stock indexes posted gains at the closing bell, climbing higher on encouraging data from the government trial for Gilead Sciences’ COVID-19 treatment, remdesivir. The antiviral
- 04/30/2020
|
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
- Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a
- 04/29/2020
|
Is Fate Therapeutics a Buy?
- The cell therapy pioneer has a promising early-stage pipeline and just landed a huge partner. What should investors make of this high-risk, high-reward stock?
- 04/29/2020
|
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to Hold at Zacks Investment Research
- Fate Therapeutics (NASDAQ:FATE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage […]
- 04/29/2020
|
Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting
- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the presentation of a new off-the-shelf, iPSC-derived, chimeric antigen receptor (CAR)-targeted cell-based cancer immunotherapy program at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting to be virtually hosted on May 12 – 15, 2020. The new preclinical program targets MHC class I related proteins A (MICA) and B (MICB), and is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics.
- 04/28/2020
|
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?
- Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?
- Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Boeing Backs Out From A Joint Venture With Embraer, Fate Of C-390 Cargo Plane Uncertain
- Boeing announced that it is withdrawing from a joint venture with the Brazilian aircraft maker Embraer.
- 04/28/2020
|
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?
|
Fate Therapeutics (NASDAQ:FATE) Upgraded to "Buy" at Zacks Investment Research
- Zacks Investment Research upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a hold rating to a buy rating in a research report report published on Thursday morning, Zacks.com reports. The firm currently has $32.00 price objective on the biopharmaceutical company’s stock. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the […]
- 04/20/2020
|
Bank of America Corp DE Trims Stake in Fate Therapeutics Inc (NASDAQ:FATE)
- Bank of America Corp DE decreased its position in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 5.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 119,285 shares of the biopharmaceutical company’s stock after selling 6,324 shares during the period. Bank of […]
- 04/19/2020
|
Fate Therapeutics (NASDAQ:FATE) & Solid Biosciences (NASDAQ:SLDB) Financial Analysis
- Solid Biosciences (NASDAQ:SLDB) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Insider and Institutional Ownership 57.8% of Solid Biosciences shares are held by institutional investors. Comparatively, 95.1% […]
- 04/19/2020
|
Fate Therapeutics (NASDAQ:FATE) Downgraded by Zacks Investment Research
- Zacks Investment Research downgraded shares of Fate Therapeutics (NASDAQ:FATE) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, […]
- 04/18/2020
|
Fate Therapeutics Inc (NASDAQ:FATE) Shares Purchased by Alliancebernstein L.P.
- Alliancebernstein L.P. increased its holdings in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,300 shares of the biopharmaceutical company’s stock after purchasing an additional 2,800 shares during the period. Alliancebernstein L.P. […]
- 04/17/2020
|
-$0.38 EPS Expected for Fate Therapeutics Inc (NASDAQ:FATE) This Quarter
- Equities research analysts expect Fate Therapeutics Inc (NASDAQ:FATE) to post ($0.38) earnings per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Fate Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.45). Fate Therapeutics reported earnings of ($0.30) per […]
- 04/16/2020
|
Fate Therapeutics Inc (NASDAQ:FATE) Stake Boosted by Bank of New York Mellon Corp
- Bank of New York Mellon Corp increased its position in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 9.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 238,509 shares of the biopharmaceutical company’s stock after purchasing an additional 19,993 shares during the quarter. Bank […]
- 04/16/2020
|
Fate Therapeutics Inc (NASDAQ:FATE) Expected to Announce Quarterly Sales of $2.07 Million
- Wall Street brokerages forecast that Fate Therapeutics Inc (NASDAQ:FATE) will report $2.07 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Fate Therapeutics’ earnings, with the lowest sales estimate coming in at $630,000.00 and the highest estimate coming in at $3.00 million. Fate Therapeutics posted […]
- 04/15/2020
|
Top Ranked Momentum Stocks to Buy for April 14th
- Top Ranked Momentum Stocks to Buy for April 14th
- 04/14/2020
|
Top Ranked Momentum Stocks to Buy for April 14th
- Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th
- 04/14/2020
|
Fate Therapeutics (NASDAQ:FATE) Raised to "Buy" at BidaskClub
- Fate Therapeutics (NASDAQ:FATE) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports. Other research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Fate Therapeutics from a “buy” rating to a “hold” rating […]
- 04/14/2020
|
Atara Biotherapeutics: Still Bullish On Long-Term Prospects
- Atara Biotherapeutics recently updated that its lead program, tab-cel, remains on track despite the COVID-19 pandemic. Tab-cel is the most advanced allogeneic T
- 04/14/2020
|
Top Ranked Momentum Stocks to Buy for April 14th
|
Fate Therapeutics (NASDAQ:FATE) Cut to "Hold" at Zacks Investment Research
- Zacks Investment Research downgraded shares of Fate Therapeutics (NASDAQ:FATE) from a buy rating to a hold rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage […]
- 04/12/2020
|
AQR Capital Management LLC Has $374,000 Stock Holdings in Fate Therapeutics Inc (NASDAQ:FATE)
- AQR Capital Management LLC cut its holdings in Fate Therapeutics Inc (NASDAQ:FATE) by 35.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,086 shares of the biopharmaceutical company’s stock after selling 10,493 shares during the quarter. AQR Capital Management LLC’s holdings in Fate Therapeutics were worth […]
- 04/12/2020
|
Fate Therapeutics (FATE) is a Great Momentum Stock: Should You Buy?
- Does Fate Therapeutics (FATE) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/10/2020
|
Fate Therapeutics (FATE) is a Great Momentum Stock: Should You Buy?
- Does Fate Therapeutics (FATE) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/10/2020
|
Investment Analysts' Weekly Ratings Changes for Fate Therapeutics (FATE)
- Fate Therapeutics (NASDAQ: FATE) has recently received a number of price target changes and ratings updates: 4/9/2020 – Fate Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of […]
- 04/10/2020
|
Why Fate Therapeutics Tumbled 23.9% in March
- The development-stage pharma company gave up a good chunk of its gains from recent months, but roared back in April.
- 04/09/2020
|
Q2 2020 Earnings Forecast for Fate Therapeutics Inc (NASDAQ:FATE) Issued By Oppenheimer
- Fate Therapeutics Inc (NASDAQ:FATE) – Investment analysts at Oppenheimer boosted their Q2 2020 earnings per share (EPS) estimates for shares of Fate Therapeutics in a research note issued on Sunday, April 5th. Oppenheimer analyst M. Biegler now anticipates that the biopharmaceutical company will post earnings of ($0.45) per share for the quarter, up from their […]
- 04/09/2020
|
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?
- Is (FATE) Outperforming Other Medical Stocks This Year?
- 04/08/2020
|
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?
- Is (FATE) Outperforming Other Medical Stocks This Year?
- 04/08/2020
|
2 Top U.S. Stocks to Watch in April
- These two stocks can be used to gauge how the pharmaceutical industry and energy sector are faring during the coronavirus pandemic -- and what might be ahead.
- 04/08/2020
|
Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results
- Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.
- 04/08/2020
|
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
- The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
- 04/08/2020
|
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
- The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
- 04/08/2020
|
Is Fate Therapeutics (FATE) Stock a Solid Choice Right Now?
- Fate Therapeutics (FATE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/08/2020
|
Is Fate Therapeutics (FATE) Stock a Solid Choice Right Now?
- Fate Therapeutics (FATE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/08/2020
|
Fate Therapeutics Inc (NASDAQ:FATE) Shares Bought by Guggenheim Capital LLC
- Guggenheim Capital LLC increased its stake in Fate Therapeutics Inc (NASDAQ:FATE) by 57.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,965 shares of the biopharmaceutical company’s stock after purchasing an additional 7,312 shares during the period. Guggenheim Capital LLC’s holdings in […]
- 04/08/2020
|
Fate Therapeutics (NASDAQ:FATE) PT Lowered to $34.00
- Fate Therapeutics (NASDAQ:FATE) had its price target dropped by stock analysts at Oppenheimer from $36.00 to $34.00 in a research report issued to clients and investors on Monday, BenzingaRatingsTable reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price suggests a potential upside of 40.61% from the company’s previous […]
- 04/08/2020
|
Fate Therapeutics Inc (NASDAQ:FATE) Receives Average Rating of "Buy" from Analysts
- Fate Therapeutics Inc (NASDAQ:FATE) has received an average recommendation of “Buy” from the nineteen brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock […]
- 04/08/2020
|
Fate Therapeutics (NASDAQ:FATE) Shares Up 6.9% on Analyst Upgrade
- Fate Therapeutics Inc (NASDAQ:FATE) shares shot up 6.9% on Monday after Piper Sandler raised their price target on the stock. The stock traded as high as $25.00 and last traded at $24.52, 801,539 shares changed hands during mid-day trading. A decline of 49% from the average session volume of 1,563,486 shares. The stock had previously […]
- 04/08/2020
|
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?
|
My Top Biotech Stocks to Buy in the Market Crash
- The worst is yet to come for the stock market, but these biopharma companies have promising potential.
- 04/07/2020
|
Fate Therapeutics (NASDAQ:FATE) Price Target Increased to $41.00 by Analysts at Wedbush
- Fate Therapeutics (NASDAQ:FATE) had its price objective upped by Wedbush from $38.00 to $41.00 in a research report sent to investors on Friday, BenzingaRatingsTable reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock. FATE has been the topic of a number of other reports. Piper Sandler raised their price objective on […]
- 04/07/2020
|
Cubist Systematic Strategies LLC Increases Stock Holdings in Fate Therapeutics Inc (NASDAQ:FATE)
- Cubist Systematic Strategies LLC boosted its position in Fate Therapeutics Inc (NASDAQ:FATE) by 884,240.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,217 shares of the biopharmaceutical company’s stock after purchasing an additional 44,212 shares during the period. Cubist Systematic Strategies LLC owned about 0.06% […]
- 04/07/2020
|
Fate Therapeutics (NASDAQ:FATE) Price Target Raised to
- Fate Therapeutics (NASDAQ:FATE) had its price objective upped by Piper Sandler in a research report released on Friday morning, The Fly reports. FATE has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Fate Therapeutics from a buy rating to a hold rating in a research note on […]
- 04/07/2020
|
Oppenheimer Maintains Outperform on Fate Therapeutics, Lowers Price Target to $34
|
What Wedbush Is Watching in Biotechs Amid Coronavirus Crisis
- In a recent report from Wedbush Securities, the boutique brokerage firm recaps the COVID-19 impact on its coverage universe. Here, 24/7 Wall St. has picked out some of Wedbush’s top picks within the sector.
- 04/06/2020
|
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
- Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- 04/06/2020
|
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
- Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- 04/06/2020
|
Franklin Resources Inc. Has $34.52 Million Stock Position in Fate Therapeutics Inc (NASDAQ:FATE)
- Franklin Resources Inc. reduced its stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 23.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,763,821 shares of the biopharmaceutical company’s stock after selling 554,900 shares during the quarter. Franklin Resources […]
- 04/06/2020
|
Fate Therapeutics (FATE) Received its Third Buy in a Row
- After SunTrust Robinson and Mizuho Securities gave Fate Therapeutics (NASDAQ: FATE) a Buy rating last month, the company received another Buy, this time
- 04/06/2020
|
Fate Therapeutics (FATE) Received its Third Buy in a Row
- After SunTrust Robinson and Mizuho Securities gave Fate Therapeutics (NASDAQ: FATE) a Buy rating last month, the company received another
- 04/06/2020
|
Fate Therapeutics (NASDAQ:FATE) Sees Strong Trading Volume on Analyst Upgrade
- Fate Therapeutics Inc (NASDAQ:FATE) shares saw unusually-strong trading volume on Friday after Piper Sandler raised their price target on the stock. Approximately 3,951,016 shares were traded during mid-day trading, an increase of 242% from the previous session’s volume of 1,154,879 shares.The stock last traded at $22.94 and had previously closed at $21.07. Other equities analysts […]
- 04/05/2020
|
Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 13%
- Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders will have a reason to smile today, with the analysts making...
- 04/04/2020
|
Need To Know: Analysts Are Much More Bullish On Fate Therapeutics, Inc. (NASDAQ:FATE) Revenues
- Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders will have a reason to smile today, with the analysts making...
- 04/04/2020
|
Coronavirus Roundtable - Strains And Hopes In The Healthcare Sector
- The healthcare sector is on the front lines of treating, preventing, and ultimately solving the coronavirus issues. We discuss with our panelists how the sector
- 04/04/2020
|
Raymond James & Associates Trims Position in Fate Therapeutics Inc (NASDAQ:FATE)
- Raymond James & Associates lessened its stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 15.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,247 shares of the biopharmaceutical company’s stock after selling 6,210 shares during the period. Raymond James & […]
- 04/04/2020
|
7 Promising Biotech Stocks in a Postpandemic World
- The life-sciences sector will emerge as a winner from the current crisis, says Eli Casdin, founder of Casdin Capital. Why Chinese biotechs look appealing
- 04/03/2020
|
Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies
- Fate Therapeutics has signed an agreement with Janssen Biotech to develop new cancer cell therapies that are derived from stem cells and landed $100
- 04/03/2020
|
Mid-Afternoon Market Update: Dow Falls 500 Points; electroCore Shares Spike Higher
- Toward the end of trading Friday, the Dow traded down 2.34% to 20913.26 while the NASDAQ fell 2.48% to 7301.42. The S&P also fell, dropping 2.53% to 2,462.91.
The U.S. is now...
- 04/03/2020
|
Fate Therapeutics Snags $3 Billion-Plus Deal With Johnson & Johnson
- The companies will be collaborating on immuno-oncology treatments.
- 04/03/2020
|
Fly Intel: Wall Street's top stories at midday MMM;TSLA;JPM;BAC;C;GS;MS;USB;WFC;BBBY;FATE;JNJ;INCY;MIC;AEHR;CHWY
- Fly Intel: Wall Street's top stories at midday MMM TSLA JPM BAC C GS MS USB WFC BBBY FATE JNJ INCY MIC AEHR CHWY
- 04/03/2020
|
Here's Why Fate Therapeutics Rose as Much as 18.7% Today
- The cellular therapy developer announced an equity investment from and a partnership with Janssen, a subsidiary of Johnson & Johnson.
- 04/03/2020
|
Fate Therapeutics Surges on Immunotherapy Deal With J&J
- Fate Therapeutics (FATE) signs agreement with J&J; subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
- 04/03/2020
|
Fate Therapeutics Surges on Immunotherapy Deal With J&J
- Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
- 04/03/2020
|
Wedbush Maintains Outperform on Fate Therapeutics, Raises Price Target to $41
|
TSLA, ET among premarket gainers
- Capricor Therapeutics (NASDAQ:CAPR) +26% on providing its CAP-1002 cell therapy under compassionate use for patients with advanced COVID-19.Fate Therapeutics (NASDAQ:FATE) +19% on J&J cell therapy
- 04/03/2020
|
Fly Intel: Pre-market Movers JNJ;TSLA;TWTR;FATE;STZ;STZ.B;PLAY;CHWY;MMM;IMMU;NNI
- Fly Intel: Pre-market Movers JNJ TSLA TWTR FATE STZ STZ.B PLAY CHWY MMM IMMU NNI
- 04/03/2020
|
17 Healthcare Stocks Moving In Friday's Pre-Market Session
- Gainers
• electroCore, Inc. (NASDAQ:ECOR) shares rose 108.98% to $1.56 during Friday's pre-market session. The most recent rating by H.C. Wainwright, on Mar 24, is at Buy...
- 04/03/2020
|
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) * BIOLASE Inc (NASDAQ: BIOL) * BioNano Genomics Inc (NASDAQ
- 04/03/2020
|
25 Stocks Moving in Friday's Pre-Market Session
- Gainers
electroCore, Inc. (NASDAQ: ECOR) shares rose 83.5% to $1.37 in pre-market trading after the company submitted emergency use authorization application to allow study and...
- 04/03/2020
|
Fate Therapeutics (NASDAQ:FATE) Given "Buy" Rating at Mizuho
- Fate Therapeutics (NASDAQ:FATE)‘s stock had its “buy” rating restated by equities researchers at Mizuho in a report issued on Friday, AnalystRatings.com reports. They currently have a $40.00 target price on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 89.84% from the company’s current price. A number of other brokerages also […]
- 04/03/2020
|
Fly Intel: Wall Street's top stories for Friday MMM;TSLA;BBBY;BAC;JPM;WFC;C;AMZN;WMT;FATE;JNJ;INCY;MIC;AEHR;CHWY
- Fly Intel: Wall Street's top stories for Friday MMM TSLA BBBY BAC JPM WFC C AMZN WMT FATE JNJ INCY MIC AEHR CHWY
- 04/03/2020
|
Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Fate Therapeutics (FATE) today and set a price target of $40.00. The company's shares
- 04/03/2020
|
Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Fate Therapeutics (
FATE
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Thursday at $21.07.
According to
TipRanks.com
, Goldstein has 0
- 04/03/2020
|
Fate Therapeutics Surges on Immunotherapy Deal With J&J
|
Fate Therapeutics up 23% after hours on J&J cell therapy deal
- Fate Therapeutics (NASDAQ:FATE) inks a global collaboration and option agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech aimed at developing cell therapies for cancer.The partnershi
- 04/02/2020
|
Fate Therapeutics Announces Worldwide Collaboration With Janssen For Novel IPSC-derived Cell-Based Cancer Immunotherapies; Co. To Receive $50M Upfront And $50M Equity Investment And Eligible To Receive Up To $1.8B
|
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets.
- 04/02/2020
|
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
- ꟷ Collaboration leverages Company’s iPSC product platform and Janssen’s proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell...
- 04/02/2020
|
Fate Therapeutics Announces First Patient Treated In First-in-Human Clinical Trial Of FT596 And Provides Corporate Update
|
Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update
- Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient has been treated in the Company’s first-in-human Phase 1 clinical trial evaluating FT596, the first cell therapy product candidate engineered with three active anti-tumor modalities, in patients with B-cell malignancies and chronic lymphocytic leukemia. FT596 is an off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a proprietary CD19-targeting CAR, a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, and a unique interleukin-15 receptor fusion (IL-15RF).
- 04/02/2020
|
Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update
- SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the...
- 04/02/2020
|
Fly Intel: After-Hours Movers PLAY;FATE;TSLA;ZUMZ;INCY;BBBY;PTON;CAKE;AEHR;CHWY;DTIL
- Fly Intel: After-Hours Movers PLAY FATE TSLA ZUMZ INCY BBBY PTON CAKE AEHR CHWY DTIL
- 04/02/2020
|
